Skip to Content

UBS ETF BBG MSCI US Liq Crp Sust USD A-d UC97

Medalist Rating as of | See UBS Investment Hub

Morningstar’s Analysis UC97

Will UC97 outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

UBS ETF BBG MSCI US Liq Crp Sust USD A-d's recent fee cut drives an upgrade to this strategy's Morningstar Medalist Rating to Silver from Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings UC97

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 7.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Pfizer Investment Enterprises Pte Ltd.

0.89 5.0 Mil
Corporate

WarnerMedia Holdings Inc.

0.88 4.9 Mil
Corporate

Pfizer Investment Enterprises Pte Ltd.

0.72 4.0 Mil
Corporate

Bank of America Corp.

0.70 4.0 Mil
Corporate

WarnerMedia Holdings Inc.

0.69 3.9 Mil
Corporate

Amgen Inc.

0.64 3.6 Mil
Corporate

Amgen Inc.

0.64 3.6 Mil
Corporate

Bank of America Corp.

0.62 3.5 Mil
Corporate

Bank of America Corp.

0.62 3.5 Mil
Corporate

Pfizer Investment Enterprises Pte Ltd.

0.61 3.4 Mil
Corporate